TICKERNERD
Menu
RMDHealthcare · Medical Instruments & Supplies

RMD Stock Forecast: ResMed, Inc. Price Predictions for 2026-2027

Last close, 18 Aug 2026
$220
−0.18% on the day

The 18 Wall Street analysts covering ResMed, Inc. hold a median 12-month price target of $235 — +6.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 17 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$32.6B
Ticker Nerd rank
71 / 100
Median analyst target
$235
Analysts covering
18
Total return, dividends reinvested
1W
−2.2%
1M
+10.5%
YTD
−8.2%
1Y
−22.5%
From 52W high
−24.5%
From 52W low
+20.3%
$183
$291
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ResMed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Volatility
96
Value
88
Issuance
84
Growth
61
Revisions
53
Accruals
43
Momentum
32
Size
7

Quality (96): The business earns solid, repeatable profits on what it owns.

Momentum (32): The shares have been drifting down relative to others.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Oct 25Jan 26Apr 26Jul 26RMDHigh $325Median $235Low $175

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says18 analysts
7 Buy10 Hold1 Sell
Low $175Median $235High $325

The green dot is the last close — the median target sits +6.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
7 Aug 2026KeybancMaintainsOverweight$260 → $255
7 Aug 2026Piper SandlerMaintainsNeutral$233 → $225
7 Aug 2026RBC CapitalMaintainsSector Perform$234 → $244
7 Aug 2026Wells FargoMaintainsEqual-Weight$225 → $215
15 July 2026MizuhoMaintainsOutperform—
15 July 2026MizuhoMaintainsOutperform$235 → $220
13 July 2026CitigroupDowngradeNeutral$270 → $235
13 July 2026CitigroupDowngradeNeutral—
10 July 2026JefferiesMaintainsHold$240 → $225
10 July 2026JefferiesMaintainsHold—
8 July 2026RBC CapitalMaintainsOutperform$321 → $276
8 July 2026RBC CapitalMaintainsOutperform—
8 July 2026Wells FargoMaintainsEqual-Weight$227 → $225
8 July 2026Wells FargoMaintainsEqual-Weight—
22 June 2026KeybancMaintainsOverweight—
17 June 2026Morgan StanleyDowngradeEqual-Weight—
15 June 2026CitigroupMaintainsBuy—
1 May 2026RBC CapitalMaintainsOutperform—
1 May 2026Wells FargoMaintainsEqual-Weight—
27 Apr 2026KeybancMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.6%
Analysts raising
3
Analysts cutting
2
Fundamentals

ResMed, Inc. (RMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.5×

Cheaper than 37% of US stocks

Price / sales
5.7×

Cheaper than 23% of US stocks

Price / book
4.9×

Cheaper than 22% of US stocks

EV / EBITDA
15.1×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
8.6%

Higher than 49% of US stocks

Earnings growth (YoY)
1.0%

Higher than 37% of US stocks

Gross margin
62.2%

Higher than 76% of US stocks

Operating margin
30.9%

Higher than 88% of US stocks

Net margin
26.9%

Higher than 87% of US stocks

Returns & dividend
Return on equity
24.3%

Higher than 85% of US stocks

Return on assets
14.0%

Higher than 96% of US stocks

Dividend yield
1.1%

Higher than 25% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
RMDResMed, Inc.$32.6B
71
ALCAlcon AG$36.1B
69
WSTWest Pharmaceutical Services, Inc.$24.9B
93
MDLNMedline, Inc.$45.8B
18
BDXBecton, Dickinson & Co.$50.2B
92
SOLVSolventum Corp.$15.1B
89
COOThe Cooper Cos., Inc.$14.7B
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ResMed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RMD news & analysis

Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor

GlobeNewsWire · 17 Aug 2026neutral

Resmed announced that Carol Burt will become Lead Director on November 15, 2026, succeeding Ron Taylor, who is not standing for reelection at the 2026 Annual Meeting on November 18, 2026, and will retire after more than 21 years of service.

Why it matters — Board leadership changes, including the successor to a long-serving director, can signal the direction of governance and oversight for Resmed shareholders.

Dividend Champion, Contender, And Challenger Highlights: Week August 16

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published a weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers, listing companies that changed their dividends and those with upcoming ex-dividend dates. The article notes the week of August 16.

Why it matters — ResMed watchers may track such summaries to stay informed of dividend-related activity relevant to the company's status as a dividend-paying stock.

ResMed Q4 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

ResMed reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, driven by increased demand for sleep devices and masks. Non-GAAP earnings per share rose 16% to $2.95, and gross margin expanded despite continued inflation in electronic components and freight.

Why it matters — The quarter showed stronger demand for sleep devices and masks alongside improved profitability, key indicators for investors tracking ResMed's growth trajectory.

RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y

Zacks Investment Research · 7 Aug 2026negative

ResMed reported fourth-quarter earnings and revenues that beat analyst estimates, with revenues rising year over year. However, shares fell after the company issued fiscal 2027 revenue guidance that trailed the consensus mark.

Why it matters — RMD watchers would care because the stock's decline despite an earnings beat signals that forward-looking guidance, rather than past-quarter results, is now driving market sentiment.

ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat

Reuters · 7 Aug 2026negative

ResMed shares fell about 6% after the company issued a fiscal 2027 revenue forecast that missed Wall Street expectations, weighed by suspended ventilator sales and cost pressures, despite beating quarterly profit estimates.

Why it matters — The weak revenue outlook suggests headwinds from suspended ventilator sales and cost pressures could weigh on ResMed's growth trajectory over the next two years.

FAQ

Frequently asked questions about RMD stock

What is the RMD stock price forecast for 2026-2027?

The 18 Wall Street analysts covering ResMed, Inc. have a median 12-month price target of $235, with estimates ranging from $175 to $325. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RMD stock a buy right now?

Of the 18 analysts covering ResMed, Inc., 7 rate it a Buy, 10 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ResMed, Inc. 71 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RMD?

As at 17 Aug 2026, ResMed, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will RMD stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +6.8% from the last close, and Ticker Nerd's factor model ranks ResMed, Inc. 71 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RMD stock forecast for 2030?

No analyst covering ResMed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $325 over the next 12 months.

How has RMD stock performed over the past year?

ResMed, Inc. returned -22.5% over the 12 months to 18 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ResMed, Inc. do?

ResMed Inc. is a healthcare company that develops and supplies digital health technologies and cloud-connected medical devices for respiratory care.

What is the latest news on RMD?

The most recent item we track (GlobeNewsWire, 17 Aug 2026): "Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor". Resmed announced that Carol Burt will become Lead Director on November 15, 2026, succeeding Ron Taylor, who is not standing for reelection at the 2026 Annual Meeting on November 18, 2026, and will retire after more than 21 years of service.

Company

About ResMed, Inc.

ResMed Inc. is a healthcare company that develops and supplies digital health technologies and cloud-connected medical devices for respiratory care. Its core products support the treatment of sleep apnea, COPD, and other chronic diseases through flow generators, masks, and related accessories used in home-based and clinical settings. ResMed also provides software and data platforms that help clinicians, patients, and care providers monitor therapy and manage ongoing treatment more effectively. The company serves healthcare systems, medical professionals, and patients across multiple regions, with a strong presence in the Americas as well as Europe, Japan, and Australia. Headquartered in San Diego, California, ResMed plays an important role in the medical instruments and supplies market by combining device-based therapy with connected digital care solutions.

CEO Mr. Michael J. Farrell BE, MBA, SM · 11,370 employees · United States · https://www.resmed.com